Oxis International Share Price Euronext Paris
Equities
US6918294025
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- EUR | - |
03-26 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-01 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.59M 4.26M 367M |
---|---|---|---|---|---|
Net income 2024 * | -17M -15.79M -1.36B | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.31
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.75% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 12/01/21 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 17/02/22 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 13/12/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 30/04/23 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 10/11/20 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 12/01/21 |
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |